GLP-1 Medication Costs: The Complete 2026 Price Guide

GLP-1 receptor agonists work by mimicking the incretin hormone GLP-1, reducing appetite, slowing gastric emptying, and improving insulin sensitivity. This guide covers the cost landscape for all FDA-approved GLP-1 medications used for weight management and type 2 diabetes, including semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound), and liraglutide (Saxenda, Victoza).

The list prices for GLP-1 medications remain substantial in 2026, though the landscape has shifted with the introduction of cash-pay options and increased competition. Ozempic (semaglutide for T2D) lists at approximately $935 per month. Wegovy (semaglutide for weight management) is the most expensive at approximately $1,349 per month. Mounjaro (tirzepatide for T2D) lists at approximately $1,023 per month, and Zepbound (tirzepatide for weight management) at approximately $1,059 per month. Rybelsus (oral semaglutide) lists at approximately $935 per month, and Saxenda (liraglutide for weight management) at approximately $1,349 per month. These are wholesale acquisition costs (WAC); actual patient costs vary enormously based on insurance coverage, deductibles, and savings programs.

• Ozempic (semaglutide, T2D): ~$935/month
• Wegovy (semaglutide, weight): ~$1,349/month
• Mounjaro (tirzepatide, T2D): ~$1,023/month
• Zepbound (tirzepatide, weight): ~$1,059/month
• Rybelsus (oral semaglutide, T2D): ~$935/month
• Saxenda (liraglutide, weight): ~$1,349/month
• Victoza (liraglutide, T2D): ~$1,000/month

Both Novo Nordisk and Eli Lilly offer manufacturer-sponsored savings programs that can dramatically reduce out-of-pocket costs for eligible patients with commercial insurance. The Novo Nordisk savings card can reduce Ozempic and Wegovy copays to as low as $25 per month for commercially insured patients, with annual limits on total savings. Eli Lilly offers the Zepbound Savings Card, which can reduce costs to $25 per month for commercially insured patients. Lilly has also introduced single-dose Zepbound vials at $399 for the 2.5 mg dose and $549 for the 5 mg dose (per month supply), available to cash-pay patients without insurance involvement. These manufacturer programs generally exclude patients on government insurance (Medicare, Medicaid, Tricare) and have annual maximum benefit caps.

• Novo Nordisk Savings Card: Ozempic/Wegovy as low as $25/month (commercially insured)
• Eli Lilly Zepbound Savings Card: as low as $25/month (commercially insured)
• Zepbound single-dose vials: $399/month (2.5 mg) or $549/month (5 mg) for cash-pay patients
• Manufacturer patient assistance programs: free medication for qualifying uninsured patients
• GoodRx and similar discount cards: may reduce pharmacy cash prices by 10-30%

Insurance coverage for GLP-1 medications depends heavily on the indication. Diabetes-indicated products (Ozempic, Mounjaro, Rybelsus, Victoza) are covered by most commercial plans and Medicare Part D, though they may require prior authorization, step therapy (trying metformin first), or be placed on higher formulary tiers with larger copays. Weight management products (Wegovy, Zepbound, Saxenda) face much more variable coverage. Many commercial plans explicitly exclude anti-obesity medications. However, coverage has improved since the SELECT cardiovascular outcomes trial demonstrated that semaglutide reduces heart attacks and strokes in obese patients. Patients should request a formulary exception or appeal from their insurer, citing the SELECT trial and the cardiovascular risk reduction indication if applicable.

• Always check your plan's formulary before starting treatment
• Ask your prescriber to submit prior authorization proactively
• If denied for a weight-loss indication, ask if the cardiovascular risk reduction indication applies
• Appeal denials with clinical documentation — success rates for first appeals are approximately 40-60%
• Consider switching to a diabetes-indicated product if you have prediabetes or T2D (better coverage)
• During open enrollment, compare plans specifically for GLP-1 coverage

Compounding pharmacies have emerged as a lower-cost alternative, offering compounded semaglutide for approximately $150-$500 per month during the FDA-declared shortage period. These products use bulk semaglutide sodium salt and are prepared by licensed 503A or 503B pharmacies. While significantly cheaper, compounded products are not FDA-approved and carry additional risks related to potency consistency, sterility, and quality control. The availability of compounded semaglutide depends on the drug's shortage status — once the FDA determines the shortage has resolved, compounders may lose their legal basis to produce it. Tirzepatide has also been compounded during its shortage period. Patients considering compounded options should verify the pharmacy's licensure and accreditation, and discuss the risks with their prescriber.

Beyond manufacturer savings programs and insurance strategies, there are additional approaches to managing GLP-1 costs. International pharmacy options exist (GLP-1 medications are often cheaper in Canada and other countries), though importation carries its own regulatory and safety considerations. Some employers are adding GLP-1 coverage to self-funded health plans in response to employee demand and evidence that treating obesity reduces downstream healthcare costs. Flexible spending accounts (FSAs) and health savings accounts (HSAs) can be used to pay for GLP-1 medications with pre-tax dollars, effectively reducing cost by your marginal tax rate. Finally, clinical trials for newer GLP-1 medications (such as oral semaglutide for weight management, survodutide, or retatrutide) may provide free access to cutting-edge treatments.

• Enroll in manufacturer savings programs before filling your first prescription
• Use an FSA or HSA to pay with pre-tax dollars
• Ask your employer about adding GLP-1 coverage during benefits review
• Check ClinicalTrials.gov for active GLP-1 trials accepting participants
• Compare prices across pharmacies — costs can vary by $100+ for the same medication
• Consider Zepbound vials ($399-$549) as a lower-cost cash-pay option